CM-3: Phase I started

Biocompatibles began a double-blind, placebo-controlled, 4-way crossover, German Phase I trial to evaluate single-ascending doses of subcutaneous CM-3 in up to 16 patients. AstraZeneca plc (LSE:AZN; ...